<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672917</url>
  </required_header>
  <id_info>
    <org_study_id>MV-0715-CP-001.01</org_study_id>
    <nct_id>NCT02672917</nct_id>
  </id_info>
  <brief_title>Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies</brief_title>
  <official_title>Phase 1 Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) With Expansion in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech Research &amp; Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9&#xD;
      Positive Malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, multicenter, non-randomized, dose escalation/expansion trial of MVT-5873 as a&#xD;
      single agent and in combination with modified FOLFIRINOX (mFOLFIRINOX) in subjects with&#xD;
      pancreatic and other CA19-9 positive malignancies. The study will define a Maximum Tolerated&#xD;
      Dose (MTD) of MVT-5873 for a Q2 week schedule (Group D), an MTD of MVT-5873 for a Q4 week&#xD;
      schedule (Group C), and an MTD for a Q2 week schedule of MVT-5873 in combination with&#xD;
      mFOLFIRINOX (Group E). Each group will utilize a conventional 3+3 study design to identify&#xD;
      the MTD and recommended phase 2 dose (RP2D).&#xD;
&#xD;
      Following the definition of an MTD in each group, the RP2D of MVT-5873 as a single agent and&#xD;
      in combination with mFOLFIRINOX will be defined. Following the completion of the dose&#xD;
      escalation phase for each group, an expansion group of up to 30 additional subjects will be&#xD;
      treated at the RP2D for each group. In Group D, subjects will be subdivided into two groups&#xD;
      of up to 15 subjects: subjects without peripheral blood expression of CA19-9 and subjects&#xD;
      with peripheral blood expression of CA19-9. MVT-5873 pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) will be determined in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety (treatment related adverse events as assessed by Common Toxicity Criteria for Adverse Events [CTCAE] V5.0) of MVT-5873 on a Q2 week schedule</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the MTD and/or RP2D of MVT-5873 on a Q2 week schedule</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the safety (treatment related adverse events as assessed by CTCAE V5.0) of MVT-5873 on a Q4 week schedule</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the MTD and/or RP2D of MVT-5873 on a Q4 week schedule</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the safety (treatment related adverse events as assessed by CTCAE V5.0) of MVT-5873 in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX)</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the MTD and/or the RP2D of MVT-5873 administered in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX)</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile (treatment related adverse events as assessed by CTCAE V5.0) of MVT-5873 in subjects without circulating CA19-9 expression</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetics (PK): Area Under the Curve (AUC) for MVT-5873</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
    <description>Determined using non-compartmental model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK: Maximum concentration (Cmax) for MVT-5873</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
    <description>Determined using non-compartmental model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK: Plasma half-life (T1/2) for MVT-5873</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
    <description>Determined using non-compartmental model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor response rate</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate duration of response</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to response</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate progression free survival</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall survival</measure>
    <time_frame>Through study completion. Estimated at one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVT-5873 is administered in Group C every 4 weeks by intravenous infusion. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVT-5873 is administered in Group D every 2 weeks by intravenous infusion. During dose escalation, doses of MVT-5873 will be increased to defined he MTD. Up to 30 patients will be treated at the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVT-5873</intervention_name>
    <description>intravenous infusion (IV)</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <other_name>HuMab-5B1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modified FOLFIRINOX (mFOLFIRINOX)</intervention_name>
    <description>IV</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Signed, informed consent&#xD;
&#xD;
          -  Age 18 or more years&#xD;
&#xD;
          -  Histologically or cytologically confirmed, locally-advanced or metastatic pancreatic&#xD;
             ductal adenocarcinoma (PDAC) or other CA19-9 positive malignancies&#xD;
&#xD;
          -  Recovered from prior treatment related toxicity to at least Grade 1 with exception of&#xD;
             Grade 2 alopecia or other Grade 2 toxicity with approval of the Medical Monitor&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 or KPS of 100%&#xD;
             to 80%&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function&#xD;
&#xD;
          -  Willingness to participate in collection of pharmacokinetic samples&#xD;
&#xD;
          -  Willingness to use adequate contraception throughout study and for a period of 3&#xD;
             months after last dose of MVT-5873&#xD;
&#xD;
        [Group C and Group D Dose Escalation]&#xD;
&#xD;
          -  Evaluable or measurable disease based on RECISTv1.1&#xD;
&#xD;
          -  Serum CA19-9 levels â‰¤ 4000 U/mL&#xD;
&#xD;
        [Group C and D]&#xD;
&#xD;
          -  Progression following treatment with standard of care for the subject's specific tumor&#xD;
             type&#xD;
&#xD;
        [Group C and D Expansion and Group E Escalation and Expansion]&#xD;
&#xD;
          -  Measurable disease based on RECISTv1.1&#xD;
&#xD;
        [Group C and D Expansion, non-PDAC malignancies]&#xD;
&#xD;
          -  If negative serum CA19-9 levels (defined as &lt; 1 U/mL or below the level of detection&#xD;
             for institutional test used), subject must have confirmation of CA19-9 expression in&#xD;
             their tumor prior to study entry&#xD;
&#xD;
        [Group E]&#xD;
&#xD;
          -  Candidates for mFOLFIRINOX based on accepted standard of care&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Brain metastases unless previously treated and well controlled for at least 3 months&#xD;
             prior to study day 1&#xD;
&#xD;
          -  Other known active cancer(s) likely to require treatment in the next two (2) years&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Fewer than 28 days (or 5 half-lives for systemic agents, whichever is shorter) from&#xD;
             prior anticancer therapy including chemotherapy, hormonal, investigational, and/or&#xD;
             biological therapies and irradiation (except for ongoing hormonal therapy for prostate&#xD;
             cancer)&#xD;
&#xD;
          -  Major surgery within 28 days of Study Day 1&#xD;
&#xD;
          -  History of anaphylactic reaction to human, or humanized, antibody&#xD;
&#xD;
          -  Pregnant or currently breast-feeding&#xD;
&#xD;
          -  Known HIV, Hepatitis B or C-positive&#xD;
&#xD;
          -  Psychiatric illness/social situations that would interfere with compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Significant cardiovascular risk (e.g., coronary stenting within 4 weeks, myocardial&#xD;
             infarction within 6 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BioNTech Responsible Person</last_name>
    <role>Study Director</role>
    <affiliation>BioNTech SE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioNTech clinical trials patient information</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>1919</phone_ext>
    <email>patients@biontech.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BioNTech clinical trial information desk</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>0</phone_ext>
    <email>info@biontech.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erkut Borazanci, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist and Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSKCC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen O'Reilly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Bauer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CA19-9 Positive Malignancies</keyword>
  <keyword>Pancreatic Cancer and other CA19-9 expressing malignancies</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma (PDAC)</keyword>
  <keyword>Sialyl Lewis A (sLea)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

